+

WO2018193090A3 - Process for preparation of eliglustat hemitartrate and intermediates thereof - Google Patents

Process for preparation of eliglustat hemitartrate and intermediates thereof Download PDF

Info

Publication number
WO2018193090A3
WO2018193090A3 PCT/EP2018/060185 EP2018060185W WO2018193090A3 WO 2018193090 A3 WO2018193090 A3 WO 2018193090A3 EP 2018060185 W EP2018060185 W EP 2018060185W WO 2018193090 A3 WO2018193090 A3 WO 2018193090A3
Authority
WO
WIPO (PCT)
Prior art keywords
intermediates
preparation
eliglustat hemitartrate
eliglustat
hemitartrate
Prior art date
Application number
PCT/EP2018/060185
Other languages
French (fr)
Other versions
WO2018193090A2 (en
Inventor
Kanaram Hanumanprasad KUMAWAT
Brijesh Rajendrakumar PATEL
Nilesh Mansukhlal Thumar
Joseph Prabahar UPADHYAY
Joseph Prabahar Koilpillai
Virendrakumar Agarwal
Parva Yogeshchandra Purohit
Arif Badrulhusan Siddiqui
Krushnakant Natvarbhai PATEL
Vipul Veljibhai GONDALIYA
Ankit Ramjibhai BUHA
Original Assignee
Amneal Pharmaceuticals Company Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amneal Pharmaceuticals Company Gmbh filed Critical Amneal Pharmaceuticals Company Gmbh
Publication of WO2018193090A2 publication Critical patent/WO2018193090A2/en
Publication of WO2018193090A3 publication Critical patent/WO2018193090A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Process for preparation of eliglustat hemitartrate and intermediates thereof Processes for preparation of eliglustat hemitartrate and intermediates thereof are provided. A stable amorphous form of eliglustat hemitartrate pharmaceutical compositions including the amorphous form of eliglustat hemitartrate, and their uses are also provided.
PCT/EP2018/060185 2017-04-21 2018-04-20 Process for preparation of eliglustat hemitartrate and intermediates thereof WO2018193090A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201721014151 2017-04-21
IN201721014151 2018-03-05

Publications (2)

Publication Number Publication Date
WO2018193090A2 WO2018193090A2 (en) 2018-10-25
WO2018193090A3 true WO2018193090A3 (en) 2019-01-03

Family

ID=62111029

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2018/060185 WO2018193090A2 (en) 2017-04-21 2018-04-20 Process for preparation of eliglustat hemitartrate and intermediates thereof

Country Status (1)

Country Link
WO (1) WO2018193090A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2796457T3 (en) 2009-11-27 2016-08-29 Genzyme Corp Genz 112 638 for the treatment of Gaucher disease or Fabry of combination therapy
CN110759885B (en) * 2018-07-27 2021-10-22 中国医学科学院药物研究所 Method for preparing photoactive igloot
CN110878079A (en) * 2018-12-31 2020-03-13 北京启慧生物医药有限公司 Preparation method of high-purity eliagliptat
US20220185788A1 (en) * 2019-03-22 2022-06-16 Piramal Pharma Limited An improved process for the preparation of eliglustat and its intermediate
CN116120274A (en) * 2021-11-12 2023-05-16 曙方(上海)医药科技有限公司 Eliglustat pharmaceutically acceptable salt and its crystal form

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004101558A1 (en) * 2003-05-13 2004-11-25 F. Hoffmann-La Roche Ag 2-imidazo-benzothiazoles as adenosine receptor ligands
US7615753B2 (en) * 2003-12-30 2009-11-10 Commissariat A L'energie Atomique Radiation detecting system with double resetting pulse count
WO2011066352A1 (en) * 2009-11-27 2011-06-03 Genzyme Corporation An amorphous and a crystalline form of genz 112638 hemitartrat as inhibitor of glucosylceramide synthase

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2399323T3 (en) 2001-07-16 2013-03-27 Genzyme Corporation Synthesis of UDP-glucose inhibitors: N-acylphingosine glucosyltransferase
US6916802B2 (en) 2002-04-29 2005-07-12 Genzyme Corporation Amino ceramide-like compounds and therapeutic methods of use
US20170129869A1 (en) 2014-07-03 2017-05-11 Dr. Reddy's Laboratories Limited Amorphous form of eliglustat hemitartarate
CN105646442A (en) 2015-10-27 2016-06-08 北京凯莱天成医药科技有限公司 Preparation method of eliglustat

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004101558A1 (en) * 2003-05-13 2004-11-25 F. Hoffmann-La Roche Ag 2-imidazo-benzothiazoles as adenosine receptor ligands
US7615753B2 (en) * 2003-12-30 2009-11-10 Commissariat A L'energie Atomique Radiation detecting system with double resetting pulse count
WO2011066352A1 (en) * 2009-11-27 2011-06-03 Genzyme Corporation An amorphous and a crystalline form of genz 112638 hemitartrat as inhibitor of glucosylceramide synthase

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"/1 -(C) FILE REGISTRY RN -2138286-91-4 REGISTRY ED -Entered STN: 02 Nov 2017 CN -Octanamide, N-[2-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-oxo-1-(1- pyrrolidinylmethyl)ethyl]-(CA INDEX NAME) MF -C23 H34 N2 O4 SR -Chemical Catalog Supplier: Enamine LLC LC -STN Files: CHEMCATS", 2 November 2017, article CHEMICAL ABSTRACTS OHIO: "/1 -(C) FILE REGISTRY RN -2138286-91-4 REGISTRY ED -Entered STN: 02 Nov 2017 CN -Octanamide, N-[2-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-oxo-1-(1- pyrrolidinylmethyl)ethyl]-(CA INDEX NAME) MF -C23 H34 N2 O4 SR -Chemical Catalog Supplier: Enamine LLC LC -STN Files: CHEMCATS", XP055491732 *

Also Published As

Publication number Publication date
WO2018193090A2 (en) 2018-10-25

Similar Documents

Publication Publication Date Title
PH12018500034A1 (en) Bicyclic lactams and methods of use thereof
WO2018193090A3 (en) Process for preparation of eliglustat hemitartrate and intermediates thereof
EP4071149A3 (en) Heterocyclic compounds and uses thereof
AU2018258581A8 (en) RAF-degrading conjugate compounds
WO2015110897A3 (en) Novel process for the preparation of dolutegravir and pharmaceutically acceptable salts thereof
TN2017000524A1 (en) New bicyclic derivatives, a process for their preparation and pharmaceutical compositions containing them
PH12020500105A1 (en) Bicyclic ketone compounds and methods of use thereof
MX393879B (en) METHODS OF PREPARATION OF NIRAPARIB.
MX2019000536A (en) Novel pyrimidine carboxamides as inhibitors of vanin-1 enzyme.
WO2015191945A3 (en) Solid state forms of sofosbuvir
WO2014125506A3 (en) A process for the preparation of ivacaftor and its intermediates
WO2016038542A3 (en) Solid forms of sofosbuvir
PH12020550125A1 (en) Crystalline forms of 3-substituted 1,2,4-oxadiazole
EP3694499A4 (en) Novel process for the preparation of lifitegrast
EP4339192A3 (en) Compounds and compositions for the treatment of cancer
WO2018125880A8 (en) Nrf2 activator
EP3615205A4 (en) Process for the preparation of deuterated ethanol from d2
WO2016108206A3 (en) Processes for preparation of idelalisib and intermediates thereof
WO2016024284A3 (en) A process for the preparation of mirabegron and its intermediates
EA201691741A1 (en) PHARMACEUTICAL COMPOSITION
EA033314B1 (en) ANTIBACTERIALS COMPRISING PYRAZINO[2,3-b][1,4]OXAZIN-3-ONE OR A RELATED RING SYSTEM
WO2015095659A3 (en) Indirubin solid dispersion composition
CA3073766A1 (en) Process for the preparation of tubulysins and intermediates thereof
MX2016013439A (en) Solid forms of a pharmaceutically active compound.
WO2016063289A3 (en) Pharmaceutical tablet compositions comprising rifaximin

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18721974

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18721974

Country of ref document: EP

Kind code of ref document: A2

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载